Bio Green Med Solution, Inc. (CYCC)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cyclacel Pharmaceuticals (CYCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024.
Bio Green Med Solution, Inc. (CYCC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bio Green Med Solution, Inc. ever had a stock split?
Bio Green Med Solution, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sing Ee Wong CEO | NASDAQ (CM) Exchange | 23254L876 CUSIP |
| US Country | 12 Employees | 29 Apr 2025 Last Dividend | 27 Aug 2012 Last Split | 5 May 2004 IPO Date |
Overview
Cyclacel Pharmaceuticals, Inc. is a prominent clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for cancer and other proliferative diseases. Established in 1996 and based in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals leverages its expertise in cell cycle, transcriptional regulation, and DNA damage response mechanisms to innovate and develop a new wave of medicines aimed at controlling the growth of cancer cells. The company is dedicated to advancing its portfolio of products through clinical trials, in collaboration with leading healthcare institutions like the University of Texas MD Anderson Cancer Center, to provide new therapeutic options for patients suffering from various hematological malignancies and solid tumors.
Products and Services
Cyclacel Pharmaceuticals, Inc. is focused on the development of novel therapeutic agents with the potential to transform cancer treatment. Two of their leading product candidates are:
- Fadraciclib: A cyclin-dependent kinase inhibitor (CDK), currently undergoing Phase 1/2 clinical trials. Fadraciclib shows promise in treating solid tumors and is also being evaluated in combination with venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). This drug aims to halt the malignant progression of cancer by targeting key enzymes involved in cell division and growth, showcasing Cyclacel’s commitment to offering innovative treatments that address gaps in cancer care.
- Plogosertib: A polo-like kinase inhibitor program in Phase 1/2 clinical trials aimed at treating advanced leukemias and solid tumors. Plogosertib represents Cyclacel’s approach towards targeting specific molecular pathways critical to cancer cell proliferation and survival, thereby providing a new strategy for combating difficult-to-treat cancers. This aligns with the company’s focus on addressing the unmet medical needs of patients facing advanced leukemias and other malignancies.
